TY - JOUR
T1 - Hepatotoxic effects of methotrexate
AU - Hersh, Evan M.
AU - Wong, Vernon G.
AU - Henderson, Edward S.
AU - Freireich, Emil J.
PY - 1966/4
Y1 - 1966/4
N2 - Hepatotoxicity of methotrexate (MTX) therapy was studied in 22 patients. During intensive MTX therapy, values for SGOT, SGPT, LDH and BSP were 140 μ, 315 μ, 753 μ and 13% with control values of 13.5 μ, 20.5 μ, 379 μ and 4%, respectively. During intermittent therapy these values were 50 μ, 110 μ, 544 μ and 10% with controls of 13 μ, 15 μ, 355 μ and 3%. Other liver function tests remained normal. After cessation of intermittent therapy, recovery occurred in one month. Liver biopsies revealed a chronic portal inflammatory reaction in 7/10. Methotrexate can be used in nonmalignant disorders provided that careful control of its toxic side effects is maintained.
AB - Hepatotoxicity of methotrexate (MTX) therapy was studied in 22 patients. During intensive MTX therapy, values for SGOT, SGPT, LDH and BSP were 140 μ, 315 μ, 753 μ and 13% with control values of 13.5 μ, 20.5 μ, 379 μ and 4%, respectively. During intermittent therapy these values were 50 μ, 110 μ, 544 μ and 10% with controls of 13 μ, 15 μ, 355 μ and 3%. Other liver function tests remained normal. After cessation of intermittent therapy, recovery occurred in one month. Liver biopsies revealed a chronic portal inflammatory reaction in 7/10. Methotrexate can be used in nonmalignant disorders provided that careful control of its toxic side effects is maintained.
UR - http://www.scopus.com/inward/record.url?scp=0013901315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0013901315&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(196604)19:4<600::AID-CNCR2820190420>3.0.CO;2-3
DO - 10.1002/1097-0142(196604)19:4<600::AID-CNCR2820190420>3.0.CO;2-3
M3 - Article
C2 - 5933584
AN - SCOPUS:0013901315
SN - 0008-543X
VL - 19
SP - 600
EP - 606
JO - Cancer
JF - Cancer
IS - 4
ER -